CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 189 enrolled
Drug / intervention
MM780G +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06834334
NCT06834334N/ACompleted

Clinical Effectiveness of Advanced Hybrid Closed-loop Systems (AHCL) for Achieving Time in Tight Range (TiTR) of Interstitial Glucose Among Adult Type 1 Diabetes (T1D) Patients

Castilla-La Mancha Health Service·observational·Posted Feb 19, 2025·Updated Mar 19, 2026

In Brief

An observational study evaluating MM780G, TTSX2, and 1 other intervention for Type 1 Diabetes (T1D). Completed, enrolled 189 participants across 3 sites.

Detailed Summary

Diabetes is a chronic disease with a relevant public health burden. Maintaining blood glucose levels as close to normal as possible is essential to avoid the associated microvascular and macrovascular complications. Therefore, the key to prevent and/or reduce the development of these chronic complications lies in an adequate and strict glycemic control. This study consist of a cross-sectional observational study among adult patients with type 1 diabetes (T1D). The main objective is to analyze the effect on time in tight range (TiTR, 70-140 mg/dL) of interstitial glucose between three different advanced hybrid closed-loop (AHCL) systems.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSpain

Timeline

N/ACompletedFinished
2026
First PostedFeb 19, 2025
Enrollment StartFeb 27, 2025
Primary CompletionOct 1, 2025
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 1.4 years ago

Interventions

MM780Gdevice

SmartGuard in Medtronic Minimed 780G advaced hybrid closed-loop

TTSX2device

Control-IQ in Tandem T Slim X2 advanced hybrid closed-loop

CamAPSdevice

CamAPS Fx in Ypsopump advanced hybrid closed-loop